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with biopsies of N2 and N3 lymph node stations is then performed in those patients with suspicious nodal disease on PET/CT, or in those with large, central pulmonary neoplasms. As will be discussed, the pathological confirmation of N2 or N3 nodal metastases will influence the types and sequence of treatment modalities utilized in these patients (see Table 1 ).
Treatment of Stage I Non-small-cell Lung Carcinoma
For patients with clinical stage I NSCLC and no medical contraindication to operative intervention, surgical resection is regarded as the sole treatment modality of choice. This is based on retrospective analyses only, as there have not been randomized clinical trials evaluating the role of surgery versus either chemotherapy or radiation therapy alone. The optimal surgical procedure of choice has been the subject of scrutiny, yet the Lung Cancer Study Group (LCSG), in its randomized controlled trial, has proved that sublobar resection has inferior results compared with lobectomy in terms of locoregional recurrence. 5 A survival difference was found in this study between the two groups in favor of the lobectomy group (p=0.08, one tailed t test). Currently, the standard of care in patients with an acceptable cardiopulmonary reserve is anatomical lobectomy for clinical stage I NSCLC.
There is an ongoing clinical trial being conducted by the Cancer and Leukemia Group B (CALGB 140503) re-examining the role of sublobar resection in patients with early-stage NSCLC. 
randomized patients with stage Ib NSCLC to receive adjuvant carboplatin and paclitaxel or observation. 9 It was believed that the tolerable treatment strategy for this select group of patients may have led to the favorable results seen with the adjuvant chemotherapeutic regimen. This survival advantage in the adjuvant arm was not seen in the recently reported update to this study. 10 A subgroup analysis suggests a benefit for those patients whose tumors are greater than 4cm.
Given the lack of supportive data for the use of adjuvant chemotherapy in patients who have undergone complete resection of stage I NSCLC, it is our practice not to routinely recommend this therapy in our patients outside of a research protocol. Recently, the Eastern Cooperative Oncology Group (ECOG) has opened an intergroup study (E1505) to examine the role of adjuvant chemotherapy with bevacizumab, an antibody against vascular endothelial growth factor, for completely resected stages I-IIIa (for stage I tumors, size must be >4cm). There is no role for adjuvant radiotherapy in completely resected stage I NSCLC based on the findings of a large meta-analysis.
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For some patients, surgery is not an option due to poor pulmonary function, comorbid disease, or simple refusal of the invasive procedure.
In lieu of surgery, these patients have received external-beam radiotherapy with modest success. Recent efforts to increase the intensity of radiation in this setting include the use of intensity-modulated radiation therapy, an example of which is stereotactic radiation. This allows for an increase in the dose delivered to the tumor while reducing the dose delivered to the normal tissues, and remains a suitable option for high-risk patients. 
Treatment of Stage II Non-small-cell Lung Carcinoma

Treatment of Stage III Non-small-cell Lung Carcinoma
Stage IIIa NSCLC covers a broad spectrum of patients, from those with tumors with chest wall invasion and hilar nodal metastases (T3N1) to patients with varying degrees of mediastinal lymph node involvement.
This latter group can then be further examined on a spectrum beginning with those with occult, micrometastatic N2 disease to patients with extracapsular, multistation, N2 nodal involvement. It is this tremendous heterogeneity, along with differing practice patterns among thoracic surgeons regarding completeness of mediastinal lymph node dissection, that has led to significant controversy regarding the optimal treatment of patients with stage IIIa NSCLC.
In addition to the aforementioned diversity of disease in these patients, there have been a wide variety of clinical trials conducted to ascertain optimal treatment strategies for this particular clinical dilemma. All utilize varying combinations of surgery, chemotherapy, and radiotherapeutic modalities. To complicate matters further, most trials are not randomized and others suffer from unreliable pre-treatment staging 
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strategies, rendering the ability to make definitive treatment recommendations quite challenging. This lack of dependable, randomized data highlights the significance of enrolling these patients in clinical trials whenever feasible.
As discussed previously, we routinely perform cervical mediastinoscopy in patients with PET/CT evidence of hilar or mediastinal lymph node involvement or in those patients with large, central malignancies. For those patients with proven N2 disease, we employ a combined multimodal approach with curative intent. The data supporting this strategy can be gleaned from adjuvant radiotherapy trials, 13 which do not demonstrate any survival advantage to slightly beneficial adjuvant chemotherapeutic studies that have been discussed. 7, 8, 12 Neoadjuvant therapy for patients with locoregionally advanced NSCLC carries potential theoretical advantages, including improved patient compliance, clearance of tumor from nodal stations resulting in downstaging and improved survival rates, and early micrometastic control of distant disease. Retrospective reports have demonstrated significantly improved survival rates in patients whose N2 nodal disease was eradicated by pre-operative therapy. 14 In this study utilizing various neoadjuvant treatment strategies, 28% of the patients had all nodal disease cleared of tumor (pN0) with a 35.8% five-year survival rate compared with an only 9% survival rate for those with residual nodal disease as determined after surgical resection.
In the 1980s, studies performed by Roth 15 and Rosell 16 were the first randomized efforts to employ neoadjuvant chemotherapy for patients with stage IIIa NSCLC. Both of these endeavors were closed early as significantly improved survival was noted in the interim analyses in the patients receiving neoadjuvant chemotherapy. The role of induction chemoradiotherapy was initially investigated by the Southwest Oncology Group (SWOG) for patients with stage IIIa and IIIb NSCLC. 17 In this phase II trial (SWOG 8805), the investigators determined that patients with persistent nodal disease at the time of surgery had a worse survival than those whose mediastinal nodal metastases were cleared with preoperative chemoradiotherapy.
The North American Intergroup 0196 trial randomized patients to either neoadjuvant chemoradiotherapy followed by surgery or definitive chemoradiotherapy. Both treatment arms received consolidation chemotherapy. The results of this endeavor have been published in abstract form and, although there was a statistically significant improvement in progression-free survival seen in the neoadjuvant chemoradiotherapy group, overall survival was comparable between the two arms. 18 The equivalent five-year survival rates between the two arms may be attributable to the particularly high mortality rate (26%) seen in patients undergoing pneumonectomy in this series.
Frequently, most patients presenting with stage IIIb NSCLC are offered definitive chemoradiotherapy for the treatment of their lung cancer, as surgical intervention offers little benefit. Although not well-studied in randomized trials specifically for stage IIIb patients, combination chemoradiotherapy has been found in a large meta-analysis to significantly increase two-and five-year survival rates compared with treatment with radiotherapy alone. 19 Completed phase III trials have determined that concurrent chemoradiotherapy results in improved two-to five-year survivalrates compared with sequential chemoradiotherapy strategies.
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A limited role of surgery has been defined in the multimodality treatment of well-selected patients with stage IIIb NSCLC. Retrospective analyses from centers performing a high volume of complex thoracic surgery procedures report acceptable rates of peri-operative morbidity and mortality in patients undergoing pulmonary resection for T4 cancers involving the carina, 21 atrium, 22 and superior vena cava. 23 Studies have also reported five-year survival rates after surgical resection of patients with intralobar satellite nodules (T4) comparable to survival seen in patients with T1 and T2 NSCLC without satellite lesions. One recent study demonstrated a median survival rate of over two years in patients with synchronous brain lesions and node-negative NSCLC primary tumors after surgical resection of the primary and either resection or stereotactic radiation therapy to the metastatic lesion. 25 There are conflicting data regarding the value of whole-brain radiation therapy in this particular patient population, and no It is certain that, other than surgery for stage I non-small-cell lung carcinoma, no one single therapeutic modality is able to achieve a cure for most patients with non-small-cell lung carcinoma. This is comparable to chemotherapy tolerance after thoracoscopic lobectomy in our hands. 28 We postulate that patients receiving Occasionally, unsuspected N2 disease is discovered and we will postpone thoracoscopic lobectomy until after the completion of neoadjuvant chemoradiotherapy. These patients will undergo clinical restaging upon the completion of neoadjuvant therapy, and a cervical mediastinoscopy will also be performed to ensure eradication of N2 nodal disease before proceeding with pulmonary resection.
We have found the multidisciplinary approach to treating patients with lung cancer to be an effective method in ensuring appropriate care in these complex clinical situations. We, along with 
